Epirubicin Ebewe (Epirubicin)
Anthracycline chemotherapy for breast cancer and bladder cancer
Epirubicin Ebewe is an anthracycline chemotherapy medicine containing the active substance epirubicin hydrochloride. It works by damaging the DNA of cancer cells, preventing them from growing and dividing. Epirubicin Ebewe is used to treat breast cancer (often in combination with other chemotherapy agents) and superficial bladder cancer (administered directly into the bladder). This medication is given only in hospitals or specialist clinics under the supervision of an experienced oncologist.
Quick Facts
Key Takeaways
- Epirubicin Ebewe is a potent anthracycline chemotherapy drug used primarily for breast cancer and superficial bladder cancer treatment
- It must be administered by healthcare professionals in a hospital setting – never self-administered
- The most serious risk is cardiotoxicity (heart damage), which is cumulative and dose-dependent – regular cardiac monitoring is essential
- Common side effects include bone marrow suppression, hair loss, nausea, and red discoloration of urine for 1–2 days after treatment
- Epirubicin is contraindicated during breastfeeding, and effective contraception is required during treatment for both men and women
What Is Epirubicin Ebewe and What Is It Used For?
Epirubicin belongs to the anthracycline family of chemotherapy agents, which are among the most effective and widely used drugs in oncology. It is a semi-synthetic derivative of doxorubicin, specifically the 4'-epimer, which gives it a slightly different pharmacological profile. Compared to doxorubicin, epirubicin is cleared from the body more quickly and tends to cause less cardiotoxicity at equivalent doses, making it a preferred choice in many treatment regimens.
The primary mechanism of action involves three key processes. First, epirubicin intercalates (inserts itself) between the base pairs of the DNA double helix, disrupting the DNA template needed for replication and transcription. Second, it inhibits topoisomerase II, an enzyme critical for managing DNA topology during replication, leading to double-strand DNA breaks. Third, it generates reactive oxygen free radicals that cause additional damage to cellular membranes and DNA.
In breast cancer, epirubicin is most commonly used as part of combination chemotherapy regimens. The FEC regimen (5-fluorouracil, epirubicin, cyclophosphamide) and EC regimen (epirubicin, cyclophosphamide) are standard treatments used in both adjuvant (after surgery) and neoadjuvant (before surgery) settings. These regimens have been extensively studied in landmark clinical trials and are recommended by major oncology guidelines including those from the European Society for Medical Oncology (ESMO) and the National Comprehensive Cancer Network (NCCN).
For superficial bladder cancer, epirubicin is instilled directly into the bladder (intravesical administration) via a catheter. This approach delivers high concentrations of the drug directly to the tumour site while minimizing systemic side effects. Intravesical epirubicin is typically used after transurethral resection of bladder tumours (TURBT) to reduce the risk of tumour recurrence. Studies have demonstrated that a single post-operative instillation can reduce the relative risk of recurrence by approximately 40%.
Epirubicin may also be used in the treatment of other cancers as determined by your oncologist, including gastric cancer, ovarian cancer, and soft tissue sarcomas, though these represent off-label uses in some jurisdictions.
What Should You Know Before Receiving Epirubicin Ebewe?
Contraindications
There are important situations where Epirubicin Ebewe must not be used. Your oncologist will carefully evaluate your medical history before starting treatment. The following are absolute contraindications to epirubicin therapy:
- You are allergic to epirubicin, other anthracyclines, or any excipient in the formulation
- You are breastfeeding
- You have severe, persistent myelosuppression (bone marrow suppression) or serious infections
- You have severely impaired liver function
- You have severe heart failure, recent myocardial infarction, or serious cardiac arrhythmias
- You have reached the maximum cumulative lifetime dose of anthracyclines or anthracenediones
- You have unstable angina pectoris or cardiomyopathy
For intravesical (bladder) administration, additional contraindications apply:
- Active urinary tract infection
- Invasive tumours that have penetrated the bladder wall
- Inflammation of the bladder (cystitis)
- Blood in the urine (haematuria)
- Difficulty with catheterisation
Warnings and Precautions
Before and during treatment with Epirubicin Ebewe, your medical team will conduct a series of monitoring tests to ensure your safety. It is essential that you communicate openly with your oncologist about your complete medical history and any symptoms you experience during treatment.
Cardiac monitoring: Heart function must be assessed before starting treatment and monitored regularly throughout the course of therapy. This typically involves echocardiography (ultrasound of the heart) or MUGA (multi-gated acquisition) scans to measure the left ventricular ejection fraction (LVEF). The cumulative dose of epirubicin should generally not exceed 900 mg/m² of body surface area to minimize the risk of irreversible heart damage. Risk factors for cardiotoxicity include pre-existing cardiovascular disease, prior or concurrent mediastinal/pericardial radiation, and previous therapy with other anthracyclines or cardiotoxic agents.
Blood count monitoring: Epirubicin causes myelosuppression, meaning it reduces the production of blood cells in the bone marrow. Complete blood counts should be performed before each treatment cycle. The nadir (lowest point) of white blood cell count typically occurs 10–14 days after administration. If your white blood cell count drops too low, treatment may need to be delayed until recovery.
Liver function: Epirubicin is primarily metabolised and eliminated by the liver. Patients with impaired liver function may experience increased toxicity and require dose reductions. Liver function tests (bilirubin, AST, ALT) should be checked before each cycle.
Extravasation: If epirubicin leaks out of the vein during intravenous infusion (extravasation), it can cause severe local tissue damage, including necrosis (tissue death). If you experience any pain, burning, or swelling at the injection site during infusion, tell your healthcare team immediately. The infusion must be stopped right away.
Your urine may turn red for 1–2 days after receiving Epirubicin Ebewe. This is normal and is caused by the red colour of the drug. It does not indicate blood in the urine and is not harmful. However, if you notice blood in your urine or other unusual symptoms, contact your healthcare team promptly.
Pregnancy and Breastfeeding
Epirubicin Ebewe can cause serious harm to an unborn child. It is critical that you inform your doctor if you are pregnant, suspect you may be pregnant, or are planning to become pregnant. The drug should not be used during pregnancy unless the potential benefit clearly outweighs the risk to the foetus and only after thorough discussion with your oncologist.
Both male and female patients should use effective contraception during treatment and for a period after the last dose. If you or your partner becomes pregnant during treatment, contact your doctor immediately for counselling about potential risks.
Male fertility: Epirubicin may cause irreversible damage to sperm production (azoospermia). Male patients of reproductive age should consider sperm banking (cryopreservation) before starting treatment.
Female fertility: Epirubicin may cause amenorrhoea (cessation of menstruation) or premature menopause in pre-menopausal women. Fertility may or may not recover after treatment ends, depending on factors such as cumulative dose and the patient's age.
Breastfeeding: Breastfeeding must be discontinued before starting Epirubicin Ebewe treatment. Epirubicin and its metabolites may pass into breast milk and could be harmful to the nursing infant.
Driving and Operating Machinery
Epirubicin itself does not directly impair the ability to drive or operate machinery. However, you may experience side effects such as nausea, fatigue, or dizziness that could affect your ability to drive safely. You are responsible for assessing your own fitness to drive. Discuss with your doctor or nurse if you have any concerns about driving during your treatment period.
Epirubicin Ebewe contains 9 mg sodium per ml. This should be taken into account by patients on a sodium-restricted diet, particularly when higher volumes are administered.
How Does Epirubicin Ebewe Interact with Other Drugs?
Drug interactions with epirubicin can be clinically significant and may either increase toxicity or reduce the effectiveness of treatment. Your oncology team will carefully review all your medications before starting epirubicin therapy. The table below summarises the most important known interactions.
Major Interactions
| Drug / Class | Interaction | Clinical Significance |
|---|---|---|
| Trastuzumab (Herceptin) | Additive cardiotoxicity; both agents can damage the heart | Avoid concurrent use; allow washout period between treatments |
| Other anthracyclines / anthracenediones | Cumulative cardiac toxicity | Lifetime anthracycline dose limits apply across all agents |
| Cyclophosphamide | Enhanced myelosuppression and potential cardiotoxicity | Used together in combination regimens with careful dose adjustment |
| Paclitaxel / Docetaxel | Paclitaxel may increase plasma levels of epirubicin if administered first | Administer epirubicin before taxanes when used sequentially |
| Live vaccines | Risk of generalised, potentially fatal infection due to immunosuppression | Live vaccines must be avoided during treatment |
Other Notable Interactions
| Drug / Class | Effect |
|---|---|
| Cimetidine | May increase epirubicin plasma levels by up to 50%; discontinue before treatment |
| Calcium channel blockers | May potentiate cardiotoxicity of epirubicin |
| Interferon alfa-2b | May reduce clearance and increase toxicity of epirubicin |
| Quinine | May accelerate distribution of epirubicin from blood into tissues |
| Dexverapamil | May increase intracellular concentration of epirubicin |
| Phenytoin | Epirubicin may reduce phenytoin levels; monitor anticonvulsant therapy |
| Chloramphenicol / Sulfonamides | May enhance haematological toxicity |
| Dexrazoxane | Cardioprotective agent; may be used to reduce anthracycline cardiotoxicity |
| Antiretroviral agents | Potential pharmacokinetic interactions; monitor closely |
If you are taking any medications not listed above, including over-the-counter medicines, nutritional supplements, or herbal remedies, always inform your oncologist or pharmacist. Some interactions may not yet be fully characterised, and your medical team can make informed adjustments to your treatment plan.
What Is the Correct Dosage of Epirubicin Ebewe?
Epirubicin Ebewe is always administered by a doctor or nurse in a hospital or specialist oncology clinic. You will never be asked to take this medication at home. The dosage is carefully calculated based on your body surface area (measured in square metres, or m²), which takes into account your height and weight, as well as your liver function, kidney function, blood counts, and overall health status.
Intravenous Administration (Breast Cancer)
For the treatment of breast cancer, epirubicin is administered intravenously (directly into a vein). The drug may be given as a bolus injection over 5–15 minutes or as a slower infusion over 30–60 minutes. Administering as an infusion over 30–60 minutes is increasingly preferred as it reduces the risk of local venous irritation and extravasation.
| Regimen | Dose | Cycle Length | Notes |
|---|---|---|---|
| FEC (adjuvant breast cancer) | 75–100 mg/m² on Day 1 | Every 21 days | Combined with 5-FU and cyclophosphamide |
| EC (adjuvant breast cancer) | 90–120 mg/m² on Day 1 | Every 21 days | Combined with cyclophosphamide |
| Single agent | 60–90 mg/m² on Day 1 | Every 21 days | Or divided over 2–3 consecutive days |
The cumulative maximum lifetime dose of epirubicin is generally considered to be 900 mg/m². Exceeding this limit significantly increases the risk of irreversible congestive heart failure. Your oncologist will carefully track your total cumulative dose throughout your treatment history.
Intravesical Administration (Bladder Cancer)
For the treatment of superficial bladder cancer, Epirubicin Ebewe is diluted in 50 ml of sterile saline and instilled directly into the bladder through a urinary catheter. A typical treatment schedule involves 8 weekly instillations of 50 mg epirubicin.
After instillation, the solution must be retained in the bladder for at least 1 hour. During this time, you will be asked to change position periodically (turn from side to side, lie on your back and stomach) to ensure that all surfaces of the bladder come into contact with the medication. After the retention period, the bladder is emptied by voiding.
Dose Adjustments
Your doctor may need to reduce the dose or delay treatment in certain situations:
- Impaired liver function: Patients with moderate liver impairment (bilirubin 1.2–3.0 mg/dl or AST 2–4 times upper limit of normal) may receive a 50% dose reduction. Patients with severe liver impairment (bilirubin >3.0 mg/dl) should generally not receive epirubicin.
- Impaired kidney function: Patients with severe renal impairment (serum creatinine >5 mg/dl) may require dose reduction.
- Low blood counts: Treatment may be delayed until blood counts recover to adequate levels.
- Elderly patients: While no specific dose reduction is required solely based on age, elderly patients are more likely to have reduced liver and cardiac function, necessitating careful assessment.
Overdose
Since Epirubicin Ebewe is administered in a hospital setting by trained healthcare professionals, an overdose is very unlikely. However, in the event of an overdose, the primary concerns would be severe myelosuppression (bone marrow failure), gastrointestinal toxicity, and acute cardiac complications. Treatment would be supportive, including blood transfusions, antibiotics for infections, and cardiac monitoring in an intensive care setting. There is no specific antidote for epirubicin overdose.
What Are the Side Effects of Epirubicin Ebewe?
Epirubicin, like all cytotoxic chemotherapy drugs, can cause a range of side effects. Not everyone will experience all of these effects, and their severity varies between patients. Your oncology team will provide supportive medications (such as anti-nausea drugs) and close monitoring to help manage side effects effectively.
- Redness, pain, or swelling at the injection site (possible extravasation)
- Rapid heartbeat, shortness of breath, or swollen ankles (possible heart damage)
- Difficulty breathing, wheezing, facial swelling, or difficulty swallowing (possible severe allergic reaction)
- Chest pain, pain when breathing, cough and breathlessness (possible pulmonary embolism)
- High fever with signs of infection (possible neutropenic sepsis)
Very Common
- Bone marrow suppression (myelosuppression) – reduced production of blood cells
- Low white blood cell count (leukopenia) – increased risk of infection
- Anaemia (low red blood cells) – fatigue and weakness
- Hair loss (alopecia) – usually reversible after treatment ends
- Red-coloured urine for 1–2 days after administration
- Nausea and vomiting
- Inflammation of mucous membranes (mucositis, stomatitis)
Common
- Infections
- Loss of appetite
- Dehydration
- Hot flushes
- Diarrhoea
- Inflammation of the gastrointestinal tract, oesophagus, and mouth
- Redness at the injection or infusion site
- Bladder inflammation (after intravesical administration)
- Burning sensation and frequent urination (after intravesical administration)
Uncommon
- Low platelet count (thrombocytopenia) – increased risk of bleeding
- Inflammation of blood vessels (phlebitis) with or without blood clots
Rare
- Secondary leukaemia (treatment-related blood cancer)
- Severe allergic reactions (anaphylaxis)
- Heart failure (chronic cardiac insufficiency)
- Cardiotoxicity – irregular heartbeat or heart muscle disease
- Very slow or fast heartbeat
- Increased uric acid levels in blood
- Dizziness
- Hives (urticaria)
- Absence of menstruation (amenorrhoea)
- Absence of sperm in semen (azoospermia)
- Fever, chills, malaise, weakness
- Abnormal liver function tests
Not Known
- Sepsis (blood poisoning) with or without shock
- Pneumonia
- Bleeding and tissue hypoxia due to bone marrow failure
- Eye inflammation (conjunctivitis, keratitis)
- Shock
- Blood clots including pulmonary embolism
- Tissue damage at injection site – rash, itching, skin changes, necrosis
- Increased skin and nail pigmentation
- Photosensitivity (increased sensitivity to sunlight)
- Radiation recall reaction (skin reaction in previously irradiated areas)
- Reduced left ventricular function (asymptomatic)
- Hardened, less elastic veins (phlebosclerosis)
- Mouth sores, oral pain, bleeding in the mouth
- Pigmentation of oral mucosa
Cardiotoxicity – Understanding the Risk
Cardiotoxicity is the most clinically important long-term side effect of epirubicin. It can manifest in two forms:
- Acute cardiotoxicity: Can occur during or shortly after administration. Typically presents as reversible arrhythmias (irregular heartbeat) or transient ECG changes. This form is usually self-limiting.
- Chronic cardiotoxicity: The more serious form, which can develop months to years after treatment. It presents as congestive heart failure with symptoms including shortness of breath, fatigue, and fluid retention. The risk is strongly related to the cumulative dose, increasing significantly when the total dose exceeds 900 mg/m².
Your oncologist will monitor your cardiac function (LVEF) throughout treatment using echocardiography or MUGA scans. If early signs of cardiac dysfunction are detected, treatment may be modified or discontinued to prevent progression to irreversible damage.
Secondary Malignancies
There is a small but documented risk of developing treatment-related acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS) following epirubicin therapy, particularly when used in combination with other cytotoxic agents or radiation therapy. This risk is generally considered acceptable given the survival benefit of adjuvant chemotherapy in breast cancer. The latency period is typically 1–3 years after treatment.
How Should You Store Epirubicin Ebewe?
Epirubicin Ebewe is a hospital-administered medication, so storage is typically managed by the hospital pharmacy and nursing staff. However, understanding proper storage is important for ensuring medication integrity and safety.
- Temperature: Store at 2–8°C (refrigerator temperature). Do not freeze.
- Light protection: Protect from light. The product should be kept in its original packaging.
- Expiry date: Do not use after the expiry date printed on the carton and vial label.
- Gel formation: If stored at low temperatures, the solution may form a gel. This gel will return to a slightly viscous to free-flowing liquid after 2–4 hours at controlled room temperature (15–25°C). This does not affect the quality of the product.
- After dilution: Once diluted, the solution should be used immediately. If not used immediately, storage should not exceed 24 hours at 2–8°C, unless dilution has been performed under validated aseptic conditions.
Epirubicin Ebewe is a cytotoxic agent and must be disposed of according to local regulations for hazardous pharmaceutical waste. It should not be disposed of via household waste or sewage systems. Hospital pharmacies have specific protocols for the safe disposal of chemotherapy drugs.
What Does Epirubicin Ebewe Contain?
Epirubicin Ebewe is supplied as a clear red solution for injection or infusion. Understanding the composition of the medicine is important for patients with known allergies or sensitivities to specific excipients.
| Component | Role | Amount |
|---|---|---|
| Epirubicin hydrochloride | Active substance | 2 mg per ml |
| Sodium chloride | Tonicity agent | 9 mg sodium per ml |
| Hydrochloric acid | pH adjustment | Quantity sufficient |
| Water for injections | Solvent | Quantity sufficient to volume |
Appearance: Clear, red solution.
Available pack sizes: 5 ml, 5 × 5 ml, 25 ml, 50 ml, and 100 ml vials. Not all pack sizes may be marketed in every country.
Compatibility: Epirubicin Ebewe is compatible with normal saline (0.9% sodium chloride) and 5% glucose infusion solutions. It must not be mixed with heparin (causes precipitation) or alkaline solutions (causes hydrolysis). It should not be mixed with other drugs in the same infusion bag or syringe unless compatibility data are available.
Frequently Asked Questions
Epirubicin and doxorubicin are both anthracycline chemotherapy drugs that work through similar mechanisms. Epirubicin is the 4'-epi-isomer of doxorubicin, meaning it has a slightly different chemical structure. The key clinical differences are that epirubicin has a shorter half-life, faster clearance from the body, and a higher maximum cumulative dose limit (900 mg/m² vs. 550 mg/m²) before significant cardiac risk occurs. This makes epirubicin somewhat less cardiotoxic at equivalent doses, though both drugs require cardiac monitoring.
Yes, in the vast majority of cases hair loss from epirubicin is reversible. Hair typically begins to regrow within 2–3 months after completing chemotherapy. The new hair may initially be a different colour or texture than before treatment, but it usually returns to normal over time. Some patients use scalp cooling (cold cap therapy) during infusion to reduce the extent of hair loss, though this is not always fully effective with anthracycline regimens.
For breast cancer, a typical course of epirubicin-based chemotherapy consists of 4–8 cycles, with each cycle lasting 21 days (3 weeks). This means the total treatment duration is usually 3–6 months. For intravesical bladder cancer treatment, the standard protocol involves 8 weekly instillations, spanning approximately 2 months. Your oncologist will determine the exact number of cycles based on your specific cancer type, stage, and response to treatment.
Epirubicin is a bright red liquid, and when it is processed and eliminated by your body, some of the drug and its coloured metabolites are excreted through the kidneys into the urine. This causes the urine to appear red or pink for approximately 1–2 days after each treatment session. This is completely normal and expected – it is not blood in the urine and does not indicate any harm to your kidneys or bladder. However, if the red colour persists beyond 2 days, or if you experience pain during urination, you should contact your healthcare team.
It is generally advisable to avoid or severely limit alcohol consumption during epirubicin treatment. Alcohol is metabolised by the liver, and since epirubicin also relies on the liver for metabolism and can affect liver function, combining the two may increase the risk of liver toxicity. Additionally, alcohol can worsen common side effects such as nausea and dehydration. Discuss your specific situation with your oncologist, who can provide personalised advice based on your overall health and treatment plan.
A fever during chemotherapy can be a sign of neutropenic sepsis, which is a medical emergency. If your temperature rises to 38°C (100.4°F) or above, or if you feel unwell with signs of infection (chills, shivering, sore throat, cough, diarrhoea, burning during urination), contact your oncology team or go to the emergency department immediately. Do not wait to see if the fever resolves on its own. Neutropenic fevers require prompt evaluation and usually intravenous antibiotics.
References
This article is based on the following peer-reviewed sources and international guidelines:
- European Medicines Agency (EMA). Epirubicin – Summary of Product Characteristics. Updated 2024. Available from: www.ema.europa.eu
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List, 2023. Epirubicin included as an essential antineoplastic medicine.
- Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–1717.
- Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(8):1194–1220. doi:10.1093/annonc/mdz173
- Sylvester RJ, Oosterlinck W, Holmang S, et al. Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma of the Bladder. Eur Urol. 2016;69(2):231–244.
- Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity. Eur Heart J. 2016;37(36):2768–2801.
- National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Breast Cancer. Version 2.2025.
- British National Formulary (BNF). Epirubicin hydrochloride. Updated 2025. Available from: bnf.nice.org.uk
About Our Medical Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, which includes board-certified oncologists and clinical pharmacologists with expertise in cancer treatment and cytotoxic drug therapy.
Content prepared by specialist medical writers with oncology training, following GRADE evidence framework and international clinical guidelines.
Reviewed by the iMedic Medical Review Board for clinical accuracy, completeness, and adherence to EMA, FDA, and WHO standards.
Our editorial process follows strict medical accuracy standards. All information is cross-referenced with approved product information (SmPC), international clinical guidelines, and peer-reviewed literature. We maintain complete editorial independence with no pharmaceutical industry funding.